Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 9/20 | 0.64 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 6/20 | 0.43 |
| ▸ | HTR2B | P41595 | 6/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907900 | 0.91 | HTR5A (0.55) | HTR5ASLC9A1HTR7HTR2BDRD2 | |
| SCHEMBL12874494 | 0.87 | HTR5A (0.47) | HTR5ASLC9A1KMT2A | |
| SCHEMBL9907883 | 0.87 | HTR5A (0.73) | HTR5ASLC9A1HTR7HTR2B | |
| SCHEMBL9907907 | 0.86 | HTR5A (0.60) | HTR5AHTR7HTR2B | |
| SCHEMBL9907899 | 0.86 | HTR5A (0.69) | HTR5AHTR7HTR2B | |
| SCHEMBL9907632 | 0.85 | KMT2A (0.49) | HTR5AKMT2A | |
| SCHEMBL9907897 | 0.84 | HTR5A (0.72) | HTR5AHTR7HTR2B | |
| SCHEMBL9907873 | 0.81 | HTR5A (0.70) | HTR5ASLC9A1HTR7HTR2BDRD2 | |
| SCHEMBL9907869 | 0.81 | HTR5A (0.61) | HTR5ASLC9A1 | |
| SCHEMBL12874527 | 0.80 | KDM4E (0.43) | HTR5AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885SLC9A1 1181/4885HTR7 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.